Laura E Niklason, the President of $HUMA ($HUMA), sold 427,459 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 17.7% of their...
Humacyte (HUMA) is advancing the field of regenerative medicine with its lab-grown blood vessels, known as acellular tissue-engineered vessels (ATEVs), poised to transform treatment options for patients...
Humacyte (HUMA), a clinical-stage biotech firm developing implantable human tissue, is set to announce its third-quarter financial results on November 8, 2024. The company, known for its acellular tissue-engineered...
Humacyte (HUMA) experienced a decline of 1.94% in its latest trading session, closing at $5.05, which was slightly more than the S&P 500's 1.86% daily loss. Over the past month, Humacyte's shares have...
Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their...